Arianna Narducci

Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study

Cristina Mussini, Andrea Giacomelli, Giuseppe Lapadula, Antonio Di Biagio et autres

Background Altered adipose tissue biology plays a key role in the development of cardiovascular disease (CVD) and cancer and contributes to mortality. We assessed the association between obesity in people with HIV (PWH) at antiretroviral therapy (ART) initiation and the risk of …

it, gb (code pays fourni par la source)

Real-world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir + rilpivirine

Greta Marchegiani, Francesco Paolo Antonucci, Ada Bertoli, Maria Concetta Bellocchi et autres

it (code pays fourni par la source)

The Forgotten Test: Missed Opportunities for HIV Diagnosis and Survival Outcomes in Advanced HIV Disease

Arianna Narducci, Alessandra Vergori, Paola Borrelli, Irene Francesca Bottalico et autres

Background: Advanced HIV disease (AHD) remains highly prevalent and is associated with increased morbidity and mortality. Missed opportunities for early diagnosis continue to represent a major public health challenge. Methods: We conducted a multicenter retrospective cohort study including antiretroviral-naive people with HIV …

it, us (code pays fourni par la source)

Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry

Tommaso Clemente, Golnaz Torkjazi, Nicolò Capra, Roberta Gagliardini et autres

Lenacapavir, the first-in-class capsid inhibitor, targets multiple stages of the HIV lifecycle, thereby inhibiting viral replication.1 Thanks to its new mechanism of action, lenacapavir is approved for use in people with HIV (PWH) who have limited treatment options.2,3 While its efficacy has …

it, vn (code pays fourni par la source)

Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort

Alessandra Vergori, Alessandro Cozzi-Lepri, Sergio Lo Caputo, Alessandro Tavelli et autres

OBJECTIVES: This analysis aimed to evaluate the rate of failure of first-line lamivudine/dolutegravir in a real-world setting and assess the effectiveness among people with HIV (PWH) at higher risk of suboptimal response. METHODS: The study included PWH from the ICONA cohort who …

it, gb, ca (code pays fourni par la source)

Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry

Daniele Armenia, Giovanni Marchegiani, Vincenzo Spagnuolo, Maria Concetta Bellocchi et autres

BACKGROUND: This study aimed to clarify whether resistance detected in HIV-1 DNA might evolve in virologically suppressed highly treatment-experienced (HTE) individuals with multidrug resistance (MDR). METHODS: Twenty-three virologically suppressed HTE MDR individuals from the PRESTIGIO Registry with two longitudinal samples available under …

it, by, us, pt (code pays fourni par la source)

All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry

Nicolò Capra, Riccardo Lolatto, Roberta Gagliardini, Tommaso Clemente et autres

People with human immunodeficiency virus (HIV) (PWH) with 4-drug class resistance (4DR) had a higher risk of death than non-4DR PWH, primarily due to lower CD4 cell counts. The priority for this vulnerable population is achieving virological control to enable immune recovery.

it, us (code pays fourni par la source)

Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era

Rebecka Papaioannu Borjesson, Sara Diotallevi, Laura Comi, Antonio Cascio et autres

BACKGROUND: CXCR4-tropic HIV seems to be associated with more clinical events than CCR5-tropic virus. OBJECTIVES: This study aims to describe the effect of the persistence of CXCR4-tropic virus on the occurrence of clinical events in people with four-class drug-resistant HIV. METHODS: This …

it, ar (code pays fourni par la source)

P26 Implementation of statin therapy in an HIV-positive cohort: real-world challenges and insights from the REPRIEVE trial

C Muscatiello, C Grillo, Arianna Narducci, Francesca Ieva et autres

OC23 Evaluation of the viral reservoir in virologically suppressed people with HIV treated with LA cabotegravir + rilpivirine regimen

Giovanni Marchegiani, Francesco Paolo Antonucci, Ada Bertoli, MC Bellocchi et autres

P27 Lost to follow-up: what’s happened? A single center analysis

Calogero Grillo, FRP Ieva, Arianna Narducci, Federica De Gregorio et autres

Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry

Tommaso Clemente, Sara Diotallevi, Davide Minisci, Riccardo Lolatto et autres

BACKGROUND: Major adverse cardiovascular events (MACEs) may contribute to the high morbidity in people with four-class drug-resistant HIV (4DR-PWH). OBJECTIVES: To explore the probability of MACEs in 4DR-PWH compared with non-4DR controls. METHODS: This was a retrospective, propensity score-matched cohort study on …

it (code pays fourni par la source)